Proteomics International Laboratories (ASX: PIQ) has secured Canadian patent protection for PromarkerEso, its first-in-class blood test for the early detection of esophageal adenocarcinoma.
Clarity Pharmaceuticals (ASX:CU6) has announced that the SECuRE trial, a Phase 1/2a study of 67Cu-SAR-bisPSMA for metastatic castration-resistant prostate cancer.
Atomo Diagnostics (ASX:AT1) has secured a purchase order worth $502,000 for its HIV self-tests, which will be supplied to an African country in March.
Respiratory imaging technology company 4DMedical (ASX:4DX) has raised $150 million through an institutional placement at $3.80 per share.
Ryman Healthcare (ASX:RYM) reported 375 sales of retirement living occupation right agreements for the quarter ended Dec. 31, 2025.
Rhythm Biosciences (ASX:RHY) has launched its updated geneType colorectal cancer risk assessment test, integrating genetic, clinical, and lifestyle factors to improve early identification of individuals at elevated risk of colorectal cancer.
Mayne Pharma (ASX:MYX) chairman Frank Condella will retire, along with two other directors, as the company moves to reduce the size of its board following a failed acquisition bid by US-based Cosette Pharmaceuticals.
Proteomics International Laboratories (ASX:PIQ) has appointed David Morris as CEO and Managing Director, effective Jan. 19.
Neuren Pharmaceuticals (ASX:NEU) highlighted key updates from its partner Acadia Pharmaceuticals' (NASXDAQ:ACAD) presentation at the 44th annual J.P. Morgan Healthcare Conference.
Australian medicinal cannabis leaders Little Green Pharma (ASX:LGP) and Cannatrek have entered into a binding scheme implementation deed, under which LGP will acquire 100% of Cannatrek’s issued capital via a scheme of arrangement.
Argent BioPharma (ASX:RGT) has entered a binding agreement with AusCann Group (ASX:ACN) to acquire AusCann's 48% equity interest in CannPal for $2 million in Argent shares at 10 cents per share.
AVITA Medical (ASX:AVH) reported preliminary unaudited results for the fourth quarter and full year of fiscal 2025, highlighting year-on-year revenue growth, a new US$60 million debt facility, and a positive revenue outlook for 2026.
